Bellerophon therapeutics announces first patient enrolled in phase 3 rebuild study evaluating inopulse® for the treatment of fibrotic interstitial lung disease

Warren, n.j., dec. 01, 2020 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its rebuild phase 3 registrational clinical study evaluating inopulse®, a pulsed inhaled nitric oxide therapy, as a potential treatment for fibrotic interstitial lung disease (fild).
BLPH Ratings Summary
BLPH Quant Ranking